In the latest close session, Sensus Healthcare, Inc. (SRTS) was up +2.54% at $4.44. The stock's change was more than the S&P 500's daily gain of 0.54%. Meanwhile, the Dow experienced a rise of 0.52%, and the technology-dominated Nasdaq saw an increase of 0.74%. Prior to today's trading, shares of the company had lost 8.65% lagged the Medical sector's loss of 2.12% and the S&P 500's gain of 4.2%.The investment community will be closely monitoring the performance of Sensus Healthcare, Inc. in its forthcoming ...

Investors in Delcath Systems, Inc. (DCTH) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 15, 2025 $7.5 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could a ...

Company Performance - Hologic (HOLX) closed at $63.26, reflecting a -2.1% change from the previous day, underperforming the S&P 500's daily loss of 0.4% [1] - The stock has decreased by 0.86% over the past month, contributing to the Medical sector's loss of 1.56%, while the S&P 500 gained 4.97% [1] Upcoming Financial Results - Hologic is set to announce its earnings on July 30, 2025, with an expected EPS of $1.05, indicating a 0.94% decline from the same quarter last year [2] - Revenue is forecasted at $1.01 billion, reflecting a 0.39% decrease compared to the corresponding quarter of the prior year [2] Full Year Projections - For the full year, earnings are projected at $4.19 per share and revenue at $4.08 billion, representing changes of +2.7% and +1.16% respectively from the prior year [3] - Recent revisions to analyst forecasts for Hologic are important as they indicate short-term business trends, with positive revisions suggesting analyst optimism [3][4] Valuation Metrics - Hologic's Forward P/E ratio is 15.41, which is a discount compared to the industry average Forward P/E of 23.06 [6] - The company has a PEG ratio of 2.37, compared to the Medical - Instruments industry's average PEG ratio of 2.24 [6] Industry Context - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 166, placing it in the bottom 33% of over 250 industries [7] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Company Performance - Intuitive Surgical, Inc. (ISRG) stock was down 2.66% at $512.06, underperforming the S&P 500's daily loss of 0.33% [1] - Over the previous month, ISRG shares gained 2.54%, outperforming the Medical sector's loss of 0.32% but underperforming the S&P 500's gain of 4.07% [1] Upcoming Earnings - The upcoming earnings report for Intuitive Surgical is expected on July 22, 2025, with a forecasted EPS of $1.92, reflecting a 7.87% increase from the same quarter last year [2] - Revenue is projected at $2.35 billion, indicating a 16.81% rise from the equivalent quarter last year [2] Full Year Estimates - For the full year, earnings are projected at $7.84 per share and revenue at $9.65 billion, showing increases of +6.81% and +15.56% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Intuitive Surgical reflect short-term business trends, with positive revisions indicating optimism about the business outlook [3] Zacks Rank - Intuitive Surgical is currently rated as Zacks Rank 2 (Buy), with the Zacks Rank system showing a strong track record of performance [5] Valuation Metrics - The company has a Forward P/E ratio of 67.09, significantly higher than the industry average of 23.76 [6] - The PEG ratio for ISRG is 4.44, compared to the Medical - Instruments industry's average PEG ratio of 2.29 [6] Industry Overview - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 168, placing it in the bottom 32% of over 250 industries [7] - Top-rated industries (top 50%) outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - Pacific Biosciences of California (PACB) closed at $1.50, with a daily increase of +1.35%, outperforming the S&P 500's gain of 0.28% [1] - The stock has increased by 27.59% over the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37% [1] Earnings Expectations - Analysts expect Pacific Biosciences to report earnings of -$0.18 per share, reflecting a year-over-year growth of 10% [2] - The revenue forecast for the upcoming quarter is $36.46 million, indicating a growth of 1.26% compared to the same quarter last year [2] Full Year Projections - For the full year, earnings are projected at -$0.64 per share and revenue at $155.12 million, showing changes of +22.89% and +0.72% respectively from the previous year [3] Analyst Sentiment - Recent adjustments to analyst estimates indicate positive sentiment towards Pacific Biosciences' business operations and profit generation capabilities [4] - The Zacks Rank system, which assesses stock performance based on estimate changes, currently ranks Pacific Biosciences as 1 (Strong Buy) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 173, placing it in the bottom 30% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Group 1 - DexCom (DXCM) is outperforming its Medical peers with a year-to-date return of approximately 7.5%, while the average return for Medical companies is -2.9% [4] - DexCom is part of the Medical - Instruments industry, which has an average return of -7.5% this year, indicating that DXCM is performing better within its specific industry [5] - The Zacks Rank for DexCom is 2 (Buy), reflecting a positive earnings outlook with a 0.2% increase in the consensus estimate for full-year earnings over the past 90 days [3] Group 2 - Bayer Aktiengesellschaft (BAYRY) has also outperformed the sector with a year-to-date increase of 59.4% and holds a Zacks Rank of 2 (Buy) [4][5] - The consensus estimate for Bayer's current year EPS has risen by 6.4% over the last three months, indicating improving analyst sentiment [5] - Bayer is part of the Large Cap Pharmaceuticals industry, which is ranked 53 and has seen a slight decline of -0.3% this year [6]

Company Performance - Sensus Healthcare, Inc. closed at $4.64, reflecting a -2.11% change from the previous day, underperforming the S&P 500's daily loss of 0.11% [1] - Over the past month, shares have appreciated by 0.42%, lagging behind the Medical sector's gain of 1.66% and the S&P 500's gain of 5.17% [1] Upcoming Earnings - Analysts expect Sensus Healthcare, Inc. to report earnings of $0.01 per share, indicating a year-over-year decline of 90% [2] - The consensus estimate for revenue is $8.8 million, representing a 4.76% decline compared to the same quarter last year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict earnings of $0.11 per share and revenue of $41.95 million, reflecting shifts of -73.17% and +0.34% respectively from the previous year [3] - Recent changes in analyst estimates suggest evolving short-term business trends, with positive revisions indicating analyst optimism regarding business and profitability [3] Zacks Rank and Valuation - Sensus Healthcare, Inc. currently holds a Zacks Rank of 5 (Strong Sell), with the Zacks Consensus EPS estimate remaining steady over the past month [5] - The company is trading at a Forward P/E ratio of 43.09, which is a premium compared to the industry average Forward P/E of 27.15 [6] Industry Context - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 181, placing it in the bottom 27% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Company Performance - Hologic (HOLX) ended the recent trading session at $65.11, demonstrating a +1.31% change from the preceding day's closing price, outperforming the S&P 500's daily gain of 0.8% [1] - The stock has climbed by 0.88% in the past month, which is below the Medical sector's gain of 3.12% and the S&P 500's gain of 5.12% [1] Earnings Projections - Hologic's upcoming earnings per share (EPS) are projected to be $1.05, reflecting a 0.94% decrease from the same quarter last year [2] - The latest consensus estimate predicts revenue to be $1.01 billion, indicating a 0.39% decrease compared to the same quarter of the previous year [2] - Full-year Zacks Consensus Estimates call for earnings of $4.19 per share and revenue of $4.08 billion, representing year-over-year changes of +2.7% and +1.16%, respectively [3] Analyst Estimates and Rankings - Recent changes to analyst estimates for Hologic suggest a direct relationship with upcoming stock price performance, with positive estimate revisions indicating optimism about the business outlook [4][3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Hologic at 4 (Sell) [5] - Over the past month, the Zacks Consensus EPS estimate has shifted 0.11% downward [5] Valuation Metrics - Hologic is trading at a Forward P/E ratio of 15.32, which is a discount compared to the average Forward P/E of 27.05 for its industry [6] - The company has a PEG ratio of 2.36, compared to the industry average PEG ratio of 2.25 [6] Industry Context - The Medical - Instruments industry, part of the Medical sector, holds a Zacks Industry Rank of 181, positioning it in the bottom 27% of all 250+ industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has atai Life Sciences N.V. (ATAI) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.atai Life Sciences N.V. is a member of our Medical group, which includes 997 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the str ...

Company Performance - Hologic (HOLX) closed at $64.14, reflecting a -1.6% change from the previous day, underperforming the S&P 500's daily loss of 0.84% [1] - Over the past month, Hologic's shares have increased by 14.77%, while the Medical sector remained flat at 0% and the S&P 500 gained 1.44% [1] Earnings Expectations - Hologic is expected to report an EPS of $1.06, unchanged from the prior-year quarter, with a revenue estimate of $1.01 billion, indicating a 0.39% decrease from the same quarter last year [2] - Full-year Zacks Consensus Estimates project earnings of $4.2 per share and revenue of $4.08 billion, representing year-over-year changes of +2.94% and +1.16%, respectively [3] Analyst Estimates and Valuation - Recent changes in analyst estimates for Hologic are crucial, as positive revisions often indicate a favorable business outlook [3] - Hologic currently has a Zacks Rank of 4 (Sell), with a Forward P/E ratio of 15.52, which is a discount compared to the industry average Forward P/E of 26.88 [5] - The PEG ratio for Hologic stands at 2.39, compared to the Medical - Instruments industry average of 2.26 [6] Industry Context - The Medical - Instruments industry is ranked 151 in the Zacks Industry Rank, placing it in the bottom 39% of over 250 industries [6] - The Zacks Rank system indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]